- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
- Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
- Dyne Therapeutics Announces CEO Transition
- Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
- Dyne Therapeutics to Present at February Investor Conferences
- Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
More ▼
Key statistics
On Friday, Dyne Therapeutics Inc (DYN:NSQ) closed at 23.86, -21.17% below its 52-week high of 30.27, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.53 |
---|---|
High | 24.21 |
Low | 23.11 |
Bid | 14.20 |
Offer | 27.60 |
Previous close | 23.65 |
Average volume | 810.47k |
---|---|
Shares outstanding | 86.18m |
Free float | 85.70m |
P/E (TTM) | -- |
Market cap | 2.04bn USD |
EPS (TTM) | -3.94 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼